Sedecim Therapeutics

Sedec Therapeutics is a private U.S. biotechnology company developing immunology-focused therapeutics by targeting dynamic protein palmitoylation and depalmitoylation pathways. The company was formed around academic discoveries from Hening Lin and is focused on translating post-translational modification biology into new treatments for autoimmune and inflammatory diseases, with additional interest in cancer immunotherapy. Public descriptions of the company emphasize small-molecule drug discovery against immune-regulatory signaling pathways, including STAT3-related biology. Sedec appears to be an active, early-stage platform biotech headquartered in Natick, Massachusetts and backed by seed financing. Historical references to "Sedecim Therapeutics" appear to relate to an older IL-16-focused venture and do not appear to be the same exact modern operating company name.